GlassScriptPhysician profile
Nina Cheung
NPI 1013177112
$1,231.82
in general payments reported to CMS, 2019-2025
20 companies · $1,013 in 2025
The $1,013 reported for 2025 was more than what 85% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $41.41 · 2022: $58.64 · 2024: $118 · 2025: $1,013.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,132.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,131.77 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $284.28 | 2024-2025 | Zepbound, Mounjaro, Omvoh |
| Corcept Therapeutics | $142.00 | 2025 | Korlym |
| Novo Nordisk INC | $126.85 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Abbvie INC. | $124.98 | 2025 | |
| Pfizer INC. | $61.74 | 2025 | |
| Astellas Pharma US INC | $60.56 | 2025 | Veozah |
| Masimo Corporation | $58.64 | 2022 | |
| Exact Sciences Corporation | $55.40 | 2025 | Cologuard Collection Kit |
| Amgen INC. | $48.19 | 2024-2025 | Evenity, Prolia |
| Radius Health, INC. | $47.53 | 2025 | Tymlos |
| Treace Medical Concepts, INC. | $37.21 | 2025 | |
| Janssen Biotech, INC. | $35.65 | 2024 | Tremfya |
| Boehringer Ingelheim Pharmaceuticals, INC. | $34.23 | 2024-2025 | Jardiance |
| Appliedvr INC | $20.02 | 2025 | Relievrx |
| Ucb, INC. | $19.67 | 2025 | Bimzelx |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Cleerly, INC. | $19.50 | 2024 | Cleerly Labs, Cleerly Ischemia |
| Takeda Pharmaceuticals U.S.A., INC. | $14.07 | 2024 | Trintellix |
| Gilead Sciences, INC. | $14.07 | 2019 | |
| Genentech USA, INC. | $13.74 | 2019 | |
| Sanofi-Aventis U.S. LLC | $13.49 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nina Cheung listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.